Prevention of type 1 diabetes

British Medical Bulletin

Volumn 99, Issue 1, 2011, Pages 73-88

  Thrower, S L ^a   Bingley, P J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Clinical trials; Immunotherapy; Intervention; Prevention; Treatment; Type 1 diabetes

Indexed keywords

ABATACEPT; AUTOANTIBODY; DACLIZAMAB; DIAPEP 277; DOCOSAHEXAENOIC ACID; ETANERCEPT; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NBI 6024; NICOTINAMIDE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VITAMIN D;

ARTHRALGIA; ARTICLE; CELLULAR IMMUNITY; DRUG ERUPTION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; FEVER; HEADACHE; HEREDITY; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; EARLY MEDICAL INTERVENTION; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INSULIN; INSULIN-SECRETING CELLS; RISK FACTORS;

EID: 80052719569     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldr020     Document Type: Article

References (59)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9. (Pubitemid 32718550)
2. Patterson CC, Dahlquist GG, Gyurus E et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009;373:2027-33.
3. Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999;16:466-71.
4. Bougneres PF, Landais P, Boisson C et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990;39:1264-72. (Pubitemid 20327064)
5. Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008;7:550-7.
6. Wong FS. Insulin-a primary autoantigen in type 1 diabetes? Trends Mol Med 2005;11:445-8. (Pubitemid 41415723)
7. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007;7:988-94. (Pubitemid 350166057)
8. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 1991;165:97-103.
9. Morran MP, Omenn GS, Pietropaolo M. Immunology and genetics of Type 1 diabetes. Mt Sinai J Med 2008;75:314-27.
10. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998;280:243-8. (Pubitemid 28178061)
11. Ziegler AG, Hummel M, Schenker M et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999;48:460-8. (Pubitemid 29106857)
12. Gardner SG, Gale EA, Williams AJ et al. Progression to diabetes in relatives with islet autoantibodies. Is it inevitable? Diabetes Care 1999;22:2049-54. (Pubitemid 30433987)
13. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33.
14. Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007;104:17040-5. (Pubitemid 350210987)
15. Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006;91:1210-7.
16. Sosenko JM, Palmer JP, Greenbaum CJ et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643-9. (Pubitemid 44115367)
17. Sosenko JM, Palmer JP, Rafkin LE et al. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to Type 1 diabetes in diabetes prevention trial-Type 1 participants. Diabetes Care 2010;88:620-5.
18. Atkinson MA. ADA Outstanding Scientific Achievement Lecture 2004, thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease? Diabetes 2005;54:1253-63. (Pubitemid 40586652)
19. Alhadj Ali M, Dayan CM. The importance of residual endogenous beta-cell preservation in type 1 diabetes. Br J Diabetes Vasc Dis 2009;9:248-53.
20. Meier JJ, Bhushan A, Butler AE et al. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005;48:2221-8. (Pubitemid 41618910)
21. Howson JMM, Walker NM, Smyth DJ et al. the Type 1 Diabetes Genetics Consortium. Analysis of 19 genes for association with type 1 diabetes in the Type 1 Diabetes Genetics Consortium families. Genes Immun 2009;10:S74-84.
22. Wentworth JM, Fourlanos S, Harrison LC. Reappraising the stereotypes of diabetes in the modern diabetogenic environment. Nat Rev Endocrinol 2009;5:483-9.
23. van der Werf N, Kroese FG, Rozing J et al. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007;23:169-83. (Pubitemid 46437842)
24. Virtanen SM, Knip M. Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age. Am J Clin Nutr 2003;78:1053-67. (Pubitemid 40003749)
25. Bortell R, Pino SC, Greiner DL et al. Closing the circle between the bedside and the bench: Toll-like receptors in models of virally induced diabetes. Ann N Y Acad Sci 2008;1150:112-22.
26. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
27. Larsson K, Elding-Larsson H, Cederwall E et al. Genetic and perinatal factors as risk for childhood type 1 diabetes. Diabetes Metab Res Rev 2004;20:429-37. (Pubitemid 40028642)
28. Atkinson MA, Rhodes CJ. Pancreatic regeneration in type 1 diabetes: dreams on a deserted islet? Diabetologia 2005;48:2200-2. (Pubitemid 41618906)
29. Ronningen KS. Genetics in the prediction of insulin-dependent diabetes mellitus: from theory to practice. Ann Med 1997;29:387-92. (Pubitemid 27520565)
30. Achenbach P, Warncke K, Reiter J et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004;53:384-92. (Pubitemid 38174554)
31. Roep BO. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann N Y Acad Sci 2007;1103:1-10. (Pubitemid 46791118)
32. Knip M, Virtanen SM, Seppa K et al. Dietary intervention in infancy and later signs of betacell autoimmunity. N Engl J Med 2010;363:1900-8.
33. Schmid S, Buuck D, Knopff A et al. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten. Diabetologia 2004;47:1130-1. (Pubitemid 38918175)
34. Baeke F, Takiishi T, Korf H et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010;10:482-96.
35. Takiishi T, Gysemans C, Bouillon R et al. Vitamin D and diabetes. Endocrinol Metab Clin North Am 2010;39:419-46.
36. Wicklow BA, Taback SP. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann N Y Acad Sci 2006;1079:310-2. (Pubitemid 44968739)
37. Chase HP, Lescheck E, Rafkin-Mervis L et al. Nutritional intervention to prevent (NIP) Type 1 diabetes, a pilot trial. Infant Child Adolesc Nut 2009;1:98-107.
38. Thrower SL, Bingley PJ. Strategies to prevent type 1 diabetes. Diab Ob Metab 2009;11:931-8.
39. DTP-1 group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
40. Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-76. (Pubitemid 40616615)
41. www.diabetestrialnet.org. (November 2010, date last accessed)
42. Nanto-Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a doubleblind, randomised controlled trial. Lancet 2008;372:1746-55.
43. Achenbach P, Barker J, Bonifacio E. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008;8:87-93.
44. Gale EA, Bingley PJ, Emmett CL et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31.
45. Chaillous L, Bouhanick B, Kerlan V et al. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control. Diabetes Metab 2010;36:64-70.
46. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 2010;6:149-57.
47. www.immunetolerance.org. (November 2010, date last accessed).
48. Mastrandrea L, Yu J, Behrens T. et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244-9.
49. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion and preservation of beta-cell function. N Engl J Med 2009;361:2143-52.
50. Ludvigsson J, Faresjo M, Hjorth M et al. GAD Treatment and insulin secretion in recent-onset Type 1 diabetes. N Engl J Med 2008;359:1509-20.
51. Lazar L, Ofan R, Weintrob N et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007;23:286-91. (Pubitemid 46851469)
52. Walter M, Philotheou A, Bonnici F et al. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009;32:2036-40.
53. Thrower SL, James L, Hall W et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009;155:156-65.
54. Orban T, Farkas K, Jalahej H et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010;34:408-15.
55. Kroon E, Martinson LA, Kadoya K et al. Pancreatic endoderm derived from human embryonicstem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008;26:443-52. (Pubitemid 351501814)
56. Abdi R, Fiorina P, Adra CN et al. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008;57:1759-67.
57. Haller MJ, Wasserfall CH, McGrail KM et al. Autologous umbilical cord blood transfusion in very young children with Type 1 diabetes. Diabetes Care 2009;32:2041-6.
58. Creusot RJ, Yaghoubi SS, Kodama K et al. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol 2008;127:176-87.
59. Phillips B, Giannoukakis N, Trucco M. Dendritic cell-based therapy in type 1 diabetes mellitus. Expert Rev Clin Immunol 2009;5:325-39.